Comparative effectiveness of nab-paclitaxel vs. paclitaxel monotherapy as first-line (1L) treatment of metastatic triple-negative breast cancer (mTNBC) in US clinical practice

T. Luhn; S. Chui; A. Hsieh; J. Yi; A. Mecke; P. Bajaj; W. Hasnain; A. Falgas; T. G.N. Ton; A. Kurian

doi:10.1093/annonc/mdy272.306

Comparative effectiveness of nab-paclitaxel vs. paclitaxel monotherapy as first-line (1L) treatment of metastatic triple-negative breast cancer (mTNBC) in US clinical practice

T. Luhn, S. Chui, A. Hsieh, J. Yi, A. Mecke, P. Bajaj, W. Hasnain, A. Falgas, T. G.N. Ton, A. Kurian

Hematology & Medical Oncology

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	viii101
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy272.306
State	Published - Oct 1 2018

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdy272.306

Cite this

Luhn, T., Chui, S., Hsieh, A., Yi, J., Mecke, A., Bajaj, P., Hasnain, W., Falgas, A., Ton, T. G. N., & Kurian, A. (2018). Comparative effectiveness of nab-paclitaxel vs. paclitaxel monotherapy as first-line (1L) treatment of metastatic triple-negative breast cancer (mTNBC) in US clinical practice. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii101. https://doi.org/10.1093/annonc/mdy272.306

Comparative effectiveness of nab-paclitaxel vs. paclitaxel monotherapy as first-line (1L) treatment of metastatic triple-negative breast cancer (mTNBC) in US clinical practice. / Luhn, T.; Chui, S.; Hsieh, A. et al.
In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, 01.10.2018, p. viii101.

Research output: Contribution to journal › Article › peer-review

Luhn, T, Chui, S, Hsieh, A, Yi, J, Mecke, A, Bajaj, P, Hasnain, W, Falgas, A, Ton, TGN & Kurian, A 2018, 'Comparative effectiveness of nab-paclitaxel vs. paclitaxel monotherapy as first-line (1L) treatment of metastatic triple-negative breast cancer (mTNBC) in US clinical practice', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii101. https://doi.org/10.1093/annonc/mdy272.306

@article{86b9760b1b884f9296afb8cd2e97082a,

title = "Comparative effectiveness of nab-paclitaxel vs. paclitaxel monotherapy as first-line (1L) treatment of metastatic triple-negative breast cancer (mTNBC) in US clinical practice",

author = "T. Luhn and S. Chui and A. Hsieh and J. Yi and A. Mecke and P. Bajaj and W. Hasnain and A. Falgas and Ton, {T. G.N.} and A. Kurian",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy272.306",

language = "English (US)",

volume = "29",

pages = "viii101",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Comparative effectiveness of nab-paclitaxel vs. paclitaxel monotherapy as first-line (1L) treatment of metastatic triple-negative breast cancer (mTNBC) in US clinical practice

AU - Luhn, T.

AU - Chui, S.

AU - Hsieh, A.

AU - Yi, J.

AU - Mecke, A.

AU - Bajaj, P.

AU - Hasnain, W.

AU - Falgas, A.

AU - Ton, T. G.N.

AU - Kurian, A.

PY - 2018/10/1

Y1 - 2018/10/1

UR - http://www.scopus.com/inward/record.url?scp=85081527972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081527972&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy272.306

DO - 10.1093/annonc/mdy272.306

M3 - Article

C2 - 32136101

SN - 0923-7534

VL - 29

SP - viii101

JO - Annals of oncology : official journal of the European Society for Medical Oncology

JF - Annals of oncology : official journal of the European Society for Medical Oncology

ER -

Comparative effectiveness of nab-paclitaxel vs. paclitaxel monotherapy as first-line (1L) treatment of metastatic triple-negative breast cancer (mTNBC) in US clinical practice

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this